pembrolizumab
merck
['core i', 'kn412']
disappointing results of kn412 on the heals of negative javelin trial; despite trend favoring high cps score it is clear that high q3 weeks cis + xrt + io is not the right strategy, 
Director of Head & Neck Oncology, Vice Chair at @WinshipAtEmory. Medical Oncologist; H&N cancer expert. Opinions=my own https://t.co/CXZsMJ6Sg2